Vera Therapeutics (VERA) Consolidated Net Income (2020 - 2026)

Vera Therapeutics (VERA) has 7 years of Consolidated Net Income data on file, last reported at -$120.6 million in Q1 2026.

• For the quarter ending Q1 2026, Consolidated Net Income fell 131.57% year-over-year to -$120.6 million; the trailing twelve-month figure through Mar 2026 stood at -$367.0 million (down 771.63% YoY), and the FY2025 full-year result was -$1000.0, up 100.0% from the prior year.
• Consolidated Net Income for Q1 2026 stood at -$120.6 million, down from -$90.6 million in the prior quarter.
• Across five years, Consolidated Net Income topped out at $91.1 million in Q4 2024 and bottomed at -$120.6 million in Q1 2026.
• The 5-year median for Consolidated Net Income is -$28.8 million (2024), against an average of -$27.8 million.
• Peak annual rise in Consolidated Net Income reached 334.44% in 2022, while the deepest fall reached 263.03% in 2022.
• A 5-year view of Consolidated Net Income shows it stood at $38.9 million in 2022, then surged by 43.21% to $55.7 million in 2023, then soared by 63.46% to $91.1 million in 2024, then sank by 199.45% to -$90.6 million in 2025, then sank by 33.12% to -$120.6 million in 2026.
• The last three Consolidated Net Income figures came in at -$120.6 million (Q1 2026), -$90.6 million (Q4 2025), and -$80.2 million (Q3 2025), per Business Quant data.

Peer Comparison